Y-king Biologics
Y-king Biologics aims to develop a proprietary antibody platform technology allowing for engineering pH-dependent antigen binding properties into any monoclonal antibody based on an immunoglobulin scaffold. The project has a broad disease focus.
Project summary
Purpose
To develop a proprietary antibody platform technology allowing for engineering pH-dependent antigen binding properties into any monoclonal antibody based on an immunoglobulin scaffold.
Host university
Technical University of Denmark (DTU)
Funding per year
DKK 6,5M
Duration
Three years
Expected outcome
Viable startup that can raise seed or Series A financing
Project leaders
See who heads the Y-king Biologics project on its mission to develop a platform to engineer pH-dependent antigen binding into monoclonal antibodies
“On a day-to-day basis, I will work towards creating the best conditions for the team to focus on science and help set the direction of the research efforts.”
Rikke Christina Nielsen
Entrepreneur in Residence